Aia Group LTD Biomarin Pharmaceutical Inc Transaction History

Aia Group LTD

$4.23 Billion
Q2 2025

A detailed history of Aia Group LTD transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Aia Group LTD holds 3,720 shares of BMRN stock, worth $213,267. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,720

Previous 3,125 19.04%

Holding current value

$213,267

Previous $220,000 7.27%

% of portfolio

0.0%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 06, 2025	BUY	$54.08 - $68.32 $32,177 - $40,650	595 Added 19.04%	3,720 $204,000
Q1 2025 May 12, 2025	SELL	$61.25 - $72.83 $35,525 - $42,241	-580 Reduced 15.65%	3,125 $220,000
Q4 2024 Feb 12, 2025	BUY	$61.93 - $70.49 $16,721 - $19,032	270 Added 7.86%	3,705 $243,000
Q3 2024 Oct 31, 2024	BUY	$69.02 - $93.84 $31,611 - $42,978	458 Added 15.38%	3,435 $241,000
Q2 2024 Jul 31, 2024	SELL	$74.43 - $92.22 $81,798 - $101,349	-1,099 Reduced 26.96%	2,977 $245,000
Q1 2024 May 06, 2024	BUY	$83.81 - $99.0 $22,293 - $26,334	266 Added 6.98%	4,076 $355,000
Q4 2023 Jan 31, 2024	SELL	$76.22 - $98.51 $42,911 - $55,461	-563 Reduced 12.87%	3,810 $367,000
Q3 2023 Nov 01, 2023	SELL	$85.07 - $94.48 $31,475 - $34,957	-370 Reduced 7.8%	4,373 $386,000
Q2 2023 Jul 28, 2023	SELL	$86.68 - $100.3 $413,203 - $478,130	-4,767 Reduced 50.13%	4,743 $411,000
Q1 2023 Apr 28, 2023	BUY	$87.74 - $117.27 $455,984 - $609,452	5,197 Added 120.5%	9,510 $924,000
Q4 2022 Jan 31, 2023	BUY	$80.93 - $108.63 $219,077 - $294,061	2,707 Added 168.56%	4,313 $446,000
Q3 2022 Nov 04, 2022	SELL	$82.16 - $96.94 $90,868 - $107,215	-1,106 Reduced 40.78%	1,606 $136,000
Q2 2022 Aug 11, 2022	BUY	$71.48 - $86.85 $193,853 - $235,537	2,712 New	2,712 $225,000

Others Institutions Holding BMRN

# of Institutions

668

Shares Held

187M

Call Options Held

1.25M

Put Options Held

992K

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.7B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aia Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Aia Group LTD with notifications on news.

Account